What are the Considerations for G-CSF in Drug Development?
In drug development, G-CSF is often evaluated for its potential to reduce myelosuppression in preclinical and clinical trials. Evaluating the risk-benefit ratio is crucial, particularly in balancing the therapeutic benefits of increased neutrophil counts against the risks of adverse effects. Toxicologists must carefully monitor patients, especially those with pre-existing conditions that may predispose them to severe side effects.
